Scarica l'app Stockscreener
11.33
5.58%
-0.67
Dopo l'orario di chiusura:
11.65
0.32
+2.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$12.00
Aprire:
$12
Volume 24 ore:
110.60K
Relative Volume:
0.78
Capitalizzazione di mercato:
$64.17M
Reddito:
$62.39M
Utile/perdita netta:
$-181.05M
Rapporto P/E:
-3.8537
EPS:
-2.94
Flusso di cassa netto:
$-142.49M
1 W Prestazione:
-3.74%
1M Prestazione:
+20.40%
6M Prestazione:
-25.70%
1 anno Prestazione:
-11.14%
Intervallo 1D:
$10.81
$12.22
Intervallo di 1 settimana:
$10.81
$14.93
Portata 52W:
$6.50
$39.50
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4244
Indirizzo
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ATRA | 11.33 | 64.17M | 62.39M | -181.05M | -142.49M | -2.94 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics Inc - GuruFocus.com
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics Reports Q3 2024 Financial Progress - TipRanks
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference - Business Wire
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00 - MarketBeat
Atara Biotherapeutics: Q3 Earnings Snapshot - Houston Chronicle
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M - Marketscreener.com
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress - Business Wire
(ATRA) On The My Stocks Page - Stock Traders Daily
Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Business Wire
Vanguard Group Inc's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus.com
Net Present Value Model: Atara Biotherapeutics Inc’s ATA-3219 - GlobalData
Hemophagocytic Lymphohistiocytosis Market to Reach New Heights in Growth by 2034, DelveInsight Predict | Incyte, Novartis, Atara Biotherapeutics, Bellicum Pharma - The Globe and Mail
(ATRA) Trading Signals - Stock Traders Daily
Atara Biotherapeutics names new COO By Investing.com - Investing.com Australia
Atara Biotherapeutics names new COO - Investing.com
Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer - Marketscreener.com
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How to Take Advantage of moves in (ATRA) - Stock Traders Daily
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - Yahoo Finance
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily
How To Trade (ATRA) - Stock Traders Daily
Atara Therapeutics appoints Cokey Nguyen as chief executive - The Pharma Letter
Atara Biotherapeutics Sees Its Stock Price Rise - Los Angeles Business Journal
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On? - MSN
Atara Biotherapeutics Inc [ATRA] President and CEO makes an insider purchase of 3,038 shares worth 20139.0. - Knox Daily
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
Atara Biotherapeutics secures $36 million in stock sale - Investing.com
Atara Biotherapeutics Shares Climb on $36 Million Direct Offering - MarketWatch
Atara Biotherapeutics Announces Board Appointment and Capital Raise - TipRanks
Atara Biotherapeutics Announces $36 Million Registered Direct Offering - StockTitan
Atara Biotherapeutics Inc’s latest rating changes from various analysts - Knox Daily
(ATRA) Proactive Strategies - Stock Traders Daily
Atara Biotherapeutics EVP sells over $7k in company stock - Investing.com India
Atara biotherapeutics EVP sells shares worth over $6,300 - Investing.com India
Atara Biotherapeutics EVP sells over $7k in company stock By Investing.com - Investing.com South Africa
Atara biotherapeutics EVP sells shares worth over $6,300 By Investing.com - Investing.com South Africa
Atara Biotherapeutics EVP sells shares worth over $7,600 - Investing.com India
Atara Biotherapeutics CEO sells over $20k in company stock - Investing.com
Atara biotherapeutics EVP sells shares worth over $12,000 - Investing.com
Atara Biotherapeutics EVP sells shares worth over $7,600 By Investing.com - Investing.com Canada
Atara biotherapeutics EVP sells shares worth over $12,000 By Investing.com - Investing.com UK
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):